Vivasc Therapeutics is built upon the proprietary Cardiac Targeting Peptide (CTP) platform technology.
CTP is a synthetic, non-naturally occurring peptide that acts as a novel vector to target the heart and has demonstrated ability to transduce:
- Normal mouse hearts in vivo (peak uptake at 15 minutes after injection)
- Explanted human heart tissue
- Human derived iPSC beating cardiomyocytes
CTP demonstrates robust transduction of normal cardiomyocytes and sparing of fibroblasts present in adjacent scar tissue. To date, CTP conjugates have transduced cardiomyocytes carrying intact cargo as diverse as nucleic acids, radioisotopes, therapeutics, and other peptides.
The above image is fluorescence microscopy of murine hearts injected with cardiac targeting peptide-cyanine 5.5-N-Hydroxysuccinimide (CTP) vs. a random peptide (RAN) at 10 mg/kg and euthanized at indicated time points.
Peak CTP uptake by heart tissue is seen at 15 min with a steady decline over time.
Source: Zahid, M., Feldman, K. S., Garcia-Borrero, G., Feinstein, T. N., Pogodzinski, N., Xu, X., Yurko, R., Czachowski, M., Wu, Y. L., Mason, N. S., & Lo, C. W. (2018). Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction. Biomolecules, 8(4), 147. https://doi.org/10.3390/biom8040147
Cardiac Targeting Peptide (CTP) Publications
Title of Paper (Year)
We show that miRNA106a targets genes that, when misregulated, have been shown to cause hypertrophy and eventual Heart Failure (HF). The addition of miRNA106a suppresses misexpressed HF genes and reverses hypertrophy. Most importantly, using a cardiac targeting peptide reversibly linked to miRNA106a, we show delivery is specific to cardiomyocytes.
In this study, we evaluated the therapeutic potential of CTP-expressing sEVs (C-sEV) for the delivery of RAGE-targeting small interfering RNA (siRNA) (siRAGE) to suppress myocarditis. siRAGE-loaded C-sEVs attenuated inflammation in both cell culture and an in vivo model of myocarditis. Taken together, C-sEVs may be a useful drug delivery vehicle for the treatment of heart disease.
In this chapter, we use CTP as an example to describe techniques for validation of cell-specific transduction as well as provide details on a technology to identify binding partner(s) for these ever-increasing plethora of tissue-specific peptides. Given the myriad cargoes CTP can deliver, as well as rapid uptake after an intravenous injection, it can be applied to deliver radioisotopes, miRNA, siRNA, peptides, and proteins of therapeutic potential for acute cardiac conditions like myocardial infarction, where the window of opportunity for salvaging at-risk myocardium is limited to 6 hrs.
Since their initial description and characterization, the field of cell penetrating peptides as vectors has exploded. The cargoes they can deliver range from other small peptides, full-length proteins, nucleic acids including RNA and DNA, liposomes, nanoparticles, and viral particles as well as radioisotopes and other fluorescent probes for imaging purposes.
Our previous work identified a 12-amino acid peptide that targets the heart, termed cardiac targeting peptide (CTP). We now quantitatively assess the bio-distribution of CTP, show a clinical application with the imaging of the murine heart, and study its mechanisms of transduction.
This study evaluated whether genetic modification of exosomes could enhance exosome delivery to heart cells and heart tissue without toxicity. Exosomes expressing cardiac-targeting peptide (CTP)-Lamp2b on the exosomal membrane (CTP-Exo) were generated by introducing vectors encoding CTP-Lamp2b into HEK 293 cells. These results suggested that CTP-Exo might be used as a therapeutic tool for heart disease.
Despite recent improvements in techniques, ablation procedures are still limited by the risk of complications from unwanted cellular damage, caused by the nonspecific delivery of ablative energy to all heart cell types. We describe an engineered nanoparticle containing a cardiac-targeting peptide (CTP) and a photosensitizer, chlorin e6 (Ce6), for specific delivery to myocytes.
Here we review the potential applications as well as hurdles to the tremendous potential of Cell Penetrating Peptides, in particular the cell-type specific peptides.
The development of cell permeable (or penetrating) peptide tagged proteins has facilitated the delivery of Cre recombinase protein into cells in culture, organotypic slide culture, or in living animals. In this report, we generated bacterially expressed, his-tagged Cre protein with either a cardiac targeting peptide or an antennapedia peptide at the C-terminus and demonstrated efficient uptake and recombination in both cell culture and mice.
Targeting stem cells holds great potential for studying the embryonic stem cell and development of stem cell-based regenerative medicine. Previous studies demonstrated that nanoparticles can serve as a robust platform for gene delivery, non-invasive cell imaging, and manipulation of stem cell differentiation. However specific targeting of embryonic stem cells by peptide-linked nanoparticles has not been reported.
A peptide able to transduce cardiac tissue specifically, delivering cargoes to the heart, would be of significant therapeutic potential for delivery of small molecules, proteins and nucleic acids. In order to identify peptide(s) able to transduce heart tissue, biopanning was performed in cell culture and in vivo with a M13 phage peptide display library.